LNTH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

367.95M

-5.92%

1.188

-25.3%

351.39M

-5.74%

1.205

-21.24%

362.63M

-4.08%

1.280

-18.47%

Estimates Revision

The market is revising Upward the revenue expectations for Lantheus Holdings, Inc. (LNTH) for FY2025, with the revenue forecasts being adjusted by 1.44% over the past three months. During the same period, the stock price has changed by 26.19%.

Revenue Estimates for FY2025

Revise Upward

+1.44%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.46%

In Past 3 Month

Stock Price

Go Up

+26.19%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast LNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNTH is 77.83 USD with a low forecast of 61.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

61.00

Averages

77.83

High

105.00

Current: 0.000

Low

61.00

Averages

77.83

High

105.00

Truist

Buy

maintain

$80 -> $82

2025-12-18

Reason

Truist

Price Target

$80 -> $82

2025-12-18

maintain

Buy

Reason

Truist raised the firm's price target on Lantheus to $82 from $80 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

Mizuho

Outperform

maintain

$60 -> $72

2025-12-17

Reason

Mizuho

Price Target

$60 -> $72

2025-12-17

maintain

Outperform

Reason

Mizuho raised the firm's price target on Lantheus to $72 from $60 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and diagnostics group as part of its 2026 outlook. Despite stock valuations trending back toward two-year highs post the Q3 reports, there is potential for further multiple expansion "under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector," the analyst tells investors in a research note.

Truist

Hold

Buy

upgrade

$80

2025-12-11

Reason

Truist

Price Target

$80

2025-12-11

upgrade

Hold

Buy

Reason

Truist upgraded Lantheus to Buy from Hold with an $80 price target.

Truist

Richard Newitter

Hold

Buy

upgrade

$61 -> $80

2025-12-11

Reason

Truist

Richard Newitter

Price Target

$61 -> $80

2025-12-11

upgrade

Hold

Buy

Reason

Truist analyst Richard Newitter upgraded Lantheus to Buy from Hold with a price target of $80, up from $61. The firm contends that the company's Q4 and FY27 growth and profit re-acceleration prospects are compelling, adding that the stock's current multiple of 11-times earnings does not reflect its double-digit revenue and EPS prospects in FY27 and beyond, the analyst tells investors in a research note.

B. Riley

Buy

downgrade

$109 -> $84

2025-09-16

Reason

B. Riley

Price Target

$109 -> $84

2025-09-16

downgrade

Buy

Reason

B. Riley lowered the firm's price target on Lantheus to $84 from $109 and keeps a Buy rating on the shares. The firm views the near-term risk for Lantheus as whether Pylarify further loses market share and that Pylarify will be surpassed by Illuccix/Gozellix before 2nd-generation Pylarify receives pass-through status in the second half of 2026, the analyst tells investors in a research note. The firm waits for a stabilization of the stock price and better visibility into the long-term growth prospects in the next 6-12 months.

TD Cowen

Buy

downgrade

$95 -> $80

2025-09-15

Reason

TD Cowen

Price Target

$95 -> $80

2025-09-15

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Lantheus to $80 from $95 and keeps a Buy rating on the shares. The firm lowered our Pylarify pricing assumptions for 2025-2026, which should begin to recover in 2027 upon potential approval of the new formulation. They also increased their OpEx estimates, resulting in decreased 2025 EPS that is consistent with the company's guidance.

Valuation Metrics

The current forward P/E ratio for Lantheus Holdings Inc (LNTH.O) is 13.30, compared to its 5-year average forward P/E of 18.96. For a more detailed relative valuation and DCF analysis to assess Lantheus Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

18.96

Current PE

13.30

Overvalued PE

30.41

Undervalued PE

7.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.37

Current EV/EBITDA

9.39

Overvalued EV/EBITDA

14.59

Undervalued EV/EBITDA

6.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.80

Current PS

3.06

Overvalued PS

4.71

Undervalued PS

2.89

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 5211.12% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 2127.26% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 5211.12% over the last month.

Sold

Bought

LNTH News & Events

Events Timeline

No data

News

7.5

01-02Globenewswire

Lantheus Sells SPECT Business to SHINE, Focuses on PET Radiodiagnostics

8.5

01-02Newsfilter

Lantheus Sells SPECT Business to SHINE, Focuses on PET Diagnostics

5.0

2025-12-24Fool

Nitorum Capital Exits Lantheus Holdings Stake with $28.2 Million Transaction

People Also Watch

Frequently Asked Questions

What is Lantheus Holdings Inc (LNTH) stock price today?

The current price of LNTH is 67.56 USD — it has decreased -0.43 % in the last trading day.

What is Lantheus Holdings Inc (LNTH)'s business?

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. The Company's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The Company's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The Company's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The Company's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.

What is the price predicton of LNTH Stock?

What is Lantheus Holdings Inc (LNTH)'s revenue for the last quarter?

Lantheus Holdings Inc revenue for the last quarter amounts to 384.01M USD, increased 1.39 % YoY.

What is Lantheus Holdings Inc (LNTH)'s earnings per share (EPS) for the last quarter?

Lantheus Holdings Inc. EPS for the last quarter amounts to 0.41 USD, decreased -77.09 % YoY.

What changes have occurred in the market's expectations for Lantheus Holdings Inc (LNTH)'s fundamentals?

How many employees does Lantheus Holdings Inc (LNTH). have?

Lantheus Holdings Inc (LNTH) has 808 emplpoyees as of January 10 2026.

What is Lantheus Holdings Inc (LNTH) market cap?

Today LNTH has the market capitalization of 4.48B USD.